Coherus Oncology, Inc. short interest in 2026
In 2026, Coherus Oncology, Inc.'s disclosed short interest ran from 24.60% of shares outstanding on 15 Jan 2026 to 14.79% on 15 Sep 2026, a change of -9.81 percentage points. The year's high was 24.60% on 15 Jan 2026 and its low 14.79% on 15 Sep 2026, averaging 19.47% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 53.59 days on 31 Jul 2026. Full history: Coherus Oncology, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 24.60% (15 Jan 2026)
- End of year
- 14.79% (15 Sep 2026)
- Change
- -9.81 pp
- High
- 24.60% (15 Jan 2026)
- Low
- 14.79% (15 Sep 2026)
- Average
- 19.47%
- Highest days to cover
- 53.59 (31 Jul 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 24.60% | 18.03 | results (8-K) |
| 30 Jan 2026 | 24.49% | 5.77 | |
| 13 Feb 2026 | 24.50% | 12.22 | |
| 27 Feb 2026 | 22.88% | 20.59 | |
| 13 Mar 2026 | 23.19% | 17.49 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 23.28% | 20.68 | |
| 15 Apr 2026 | 23.14% | 34.70 | |
| 30 Apr 2026 | 18.03% | 25.51 | |
| 15 May 2026 | 18.22% | 17.16 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.07% | 23.66 | |
| 15 Jun 2026 | 16.62% | 33.41 | |
| 30 Jun 2026 | 16.84% | 21.88 | |
| 15 Jul 2026 | 15.49% | 24.36 | |
| 31 Jul 2026 | 15.88% | 53.59 | |
| 14 Aug 2026 | 15.53% | 19.71 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 15.48% | 16.84 | |
| 15 Sep 2026 | 14.79% | 32.76 |
See also: Coherus Oncology, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.